The Cure Coin Award aims to honor and bring public attention to the outstanding work of industry scientists developing ground-breaking scientific discoveries into lifesaving therapeutics for Alzheimer's, CTE and other related Dementias. While government and charity funded basic research produce a steady stream of headline-grabbing discoveries each year, we depend on bioindustry companies to develop those discoveries into lifesaving therapeutics for patients. Quite simply, any new medication likely to save our lives will be developed by a drug company. Most likely, a small bio startup led by scientists willing to leave the comfort zone of academia to form companies, so potentially lifesaving discoveries can go from the pages of medical journals to be developed to treatments and cures for patients. Millions of us are waiting for a cure. If we want to see these life-saving cures developed in our lifetimes, it is essential for all of us to be aware of this vital work and to join together as investors and stockholders to support it. The Cure Coin award symbolizes the power and responsibility we all share to invest our spare change and partner with the scientists working to save our lives.
The InvestAcure 2019 Cure Coin Award reception took place on July 15th, during the 2019 Alzheimer's Association International Conference in Los Angeles and featured keynotes from NFL ‘Super Agent’ Leigh Steinberg and former Vice-Chairman of the NASDAQ David Weild IV, as well as a presentation by Max Tokarsky, CEO & Founder of InvestAcure, of InvestAcure’s plan to drive $1 billion in new annual investment for Alzheimer's until a cure is found.
Hugo Geerts, PhD
For his work at Janssen contributing to the development of Razadyne, one of only five FDA approved medications for Alzheimer's, as a treatment to slow the progression of symptoms in mild to moderate disease, and for his work at In Silico Biosciences on computer modeling to advance clinical trial design.
Leen Kawas, PhD
For her work in the advancement of NDX-1017, a clinical investigational drug designed to slow, halt or potentially reverse the effects of Alzheimer's disease by amplifying the activity of a key brain growth factor, impacting neurodegeneration and promoting the regeneration of lost brain connections and network.